{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "FlublokPI",
    "source_pdf": "data/clinical_files/FlublokPI.pdf",
    "total_pages": 5,
    "total_blocks": 112,
    "total_characters": 26849
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "relevance_explanation": "This quote explicitly states that Flublok Quadrivalent was evaluated in a pivotal trial (Study 6) against Fluarix Quadrivalent, a standard-dose quadrivalent influenza vaccine, confirming the claim."
    },
    {
      "id": 2,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). ... Comparator in this study was Fluarix Quadrivalent, manufactured by GlaxoSmithKline.",
      "relevance_explanation": "This quote details the design of Study 6, specifying that Flublok Quadrivalent was directly compared to Fluarix Quadrivalent, supporting the claim that these two vaccines were evaluated against each other in the pivotal trial."
    }
  ],
  "model_used": "gpt-4.1"
}